Pfizer (Pfizer) Retained Earnings

: $118,353 Mil (As of Dec. 2023)

View and export this data going back to 1951. Start your Free Trial

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Pfizer's retained earnings for the quarter that ended in Dec. 2023 was $118,353 Mil.

Pfizer's quarterly retained earnings declined from Jun. 2023 ($128,796 Mil) to Sep. 2023 ($126,411 Mil) and declined from Sep. 2023 ($126,411 Mil) to Dec. 2023 ($118,353 Mil).

Pfizer's annual retained earnings increased from Dec. 2021 ($103,394 Mil) to Dec. 2022 ($125,656 Mil) but then declined from Dec. 2022 ($125,656 Mil) to Dec. 2023 ($118,353 Mil).

Pfizer Retained Earnings Historical Data

The historical data trend for Pfizer's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pfizer Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

97,670.00

90,392.00

103,394.00

125,656.00

118,353.00

Pfizer Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Retained Earnings																125,656.00	131,102.00	128,796.00	126,411.00	118,353.00

Pfizer Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Pfizer (NYSE:PFE) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Pfizer (Pfizer) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pfizer Inc (NYSE:PFE) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

PFE:Peru PFE:Mexico PFE_KZ:Kazakhstan 1PFE:Italy PFEd:UK 0Q1N:UK PFEB:Germany PFE:Germany PFE:Germany PFE:Germany PFE:Germany PFE:Chile PFE:Canada PFIZ34:Brazil PFE:Austria PFE:Argentina

Address

66 Hudson Boulevard East, New York, NY, USA, 10001-2192

Website

https://www.pfizer.com

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

Executives

Scott Gottlieb	director	MOLECULAR INSIGHT PHARMACEUTICALS, 160 SECOND STREET, CAMBRIDGE MA 02142
Christoffel Boshoff	officer: Executive Vice President	66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192
Jennifer B. Damico	officer: SVP & Controller	C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Payal Sahni	officer: Executive Vice President	ATTN: PFIZER CORP. SECRETARY, 235 EAST 42ND ST., NEW YORK NY 10017
Carapezzi William R Jr	officer: Executive Vice President	600 MOUNTAIN AVENUE, MURRAY HILL NJ 07921
Douglas M Lankler	officer: Senior Vice President	PFIZER INC. ATTN: CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Mikael Dolsten	officer: Senior Vice President	5 GIRALDA FARMS, MADISON NJ 07940
David M Denton	officer: Chief Financial Officer & EVP	1000 LOWE'S BOULEVARD, MOORESVILLE NC 28117
William Pao	officer: Executive Vice President	C/O CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Michael Mcdermott	officer: Executive Vice President	C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, 235 EAST 42ND STREET NY 10017
Rady A Johnson	officer: Executive Vice President	PFIZER INC. ATTN CORP. SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Alexander R Mackenzie	officer: Executive Vice President	C/O PFIZER CORP. SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Sally Susman	officer: Senior Vice President	767 FIFTH AVE, EOTIC LAWDER CORP, NEW YORK NY 10153
Angela Hwang	officer: Group President	235 EAST 42ND STREET, ATTN: CORPORATE SECRETARY, NEW YORK NY 10017
John D Young	officer: Business Unit President	C/O CORPORATE SECRETARY, 235 EAST 42ND ST., NEW YORK NY 10017